Study Status: Enrolling by invitation
Recruit Status: Enrolling by invitation
Study Type: Interventional
Official Title: Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment
Brief Summary: This is a prospective, open-label study with no patient randomization. Treatment for atypical hemolytic uremic syndrome (aHUS) will remain observational and at the discretion of the treating physician. The purpose of this study is to assess disease manifestations of complement mediated thrombotic microangiopathy (TMA) and potential clinical predictors of disease manifestations and progression in patients with aHUS with or without eculizumab treatment in the clinical setting.